Roger Li, MD

Articles

Dr Li on Safety Data Derived From the CORE-001 Trial in BCG-Unresponsive NMIBC

August 30th 2024

Roger Li, MD, discusses safety data from the final analysis of the CORE-001 trial in BCG-unresponsive non–muscle-invasive bladder cancer.

Dr Li on Cretostimogene Grenadenorepvec Plus Pembrolizumab in BCG-Unresponsive NMIBC

August 29th 2024

Roger Li, MD, discusses the final analysis of the CORE-001 trial of cretostimogene grenadenorepvec plus pembrolizumab in BCG-unresponsive NMIBC with CIS.

Dr Li on the Clinical Implications of a Post Hoc Analysis of KEYNOTE-057 in BCG-Unresponsive NMIBC

August 22nd 2024

Roger Li, MD, discusses the implications of a post hoc analysis of the KEYNOTE-057 trial in BCG-unresponsive, high-risk non–muscle-invasive bladder cancer.

Dr Li on the Rationale for a Post Hoc Analysis of KEYNOTE-057 in BCG-Unresponsive NMIBC

August 13th 2024

Roger Li, MD, details a post hoc analysis of patients with BCG-unresponsive non–muscle-invasive bladder cancer who did not respond to pembrolizumab.

Dr Li on Unmet Needs in High-Risk MIBC

July 23rd 2024

Roger Li, MD, discusses persisting unmet needs in high-risk, muscle-invasive bladder cancer.

Dr Li on Patient Outcomes From the KEYNOTE-057 Trial in BCG-Unresponsive NMIBC

June 20th 2024

Roger Li, MD, discusses patient outcomes from the KEYNOTE-057 trial in BCG–unresponsive, high-risk non–muscle-invasive bladder cancer.

Dr Li on the Rationale of the MoonRISe-1 Trial in NMIBC

May 5th 2024

Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).

Dr Li on the Rationale for Evaluating CG0070 Plus Pembrolizumab in BCG-Unresponsive NMIBC

August 7th 2023

Roger Li, MD, expands on the mechanism of action for the combination of CG0070 and pembrolizumab, and discusses the rationale for investigating the regimen's synergy in patients with non–muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guérin.

Dr Li on the Use of CG0070 Plus Pembrolizumab in BCG-Unresponsive Non–muscle Invasive Bladder Cancer

April 29th 2023

Roger Li, MD, discusses phase 2 data with the combination of CG0070 and pembrolizumab in patients with non–muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin.